ahlam1399
08-30-2016, 03:31 PM
BRIEF-Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin
* Kamada meets primary endpoint of U.S. Phase 2 study ofinhaled Alpha-1 Antitrypsin for the treatment of Alpha-1Antitrypsin deficiencyhttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=KflT2BmSuN0:bs9FxlQpTaE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=KflT2BmSuN0:bs9FxlQpTaE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=KflT2BmSuN0:bs9FxlQpTaE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=KflT2BmSuN0:bs9FxlQpTaE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=KflT2BmSuN0:bs9FxlQpTaE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/KflT2BmSuN0
* Kamada meets primary endpoint of U.S. Phase 2 study ofinhaled Alpha-1 Antitrypsin for the treatment of Alpha-1Antitrypsin deficiencyhttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=KflT2BmSuN0:bs9FxlQpTaE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=KflT2BmSuN0:bs9FxlQpTaE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=KflT2BmSuN0:bs9FxlQpTaE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=KflT2BmSuN0:bs9FxlQpTaE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=KflT2BmSuN0:bs9FxlQpTaE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/KflT2BmSuN0